Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (?BioCopy?). The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen?s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.

BioCopy will use Biocytogen?s TCR-mimic antibodies and test them against promising intracellular tumor associated antigens. Here, BioCopy will use its automated end-to-end platform for the optimization of multispecific biotherapeutics to further develop these TCR-mimic antibodies into next-generation oncological drugs.